"Tacrolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
| Descriptor ID |
D016559
|
| MeSH Number(s) |
D02.540.505.810
|
| Concept/Terms |
Anhydrous Tacrolimus- Anhydrous Tacrolimus
- Tacrolimus, Anhydrous
- Tacrolimus Anhydrous
- Anhydrous, Tacrolimus
|
Below are MeSH descriptors whose meaning is more general than "Tacrolimus".
Below are MeSH descriptors whose meaning is more specific than "Tacrolimus".
This graph shows the total number of publications written about "Tacrolimus" by people in this website by year, and whether "Tacrolimus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 8 | 2 | 10 |
| 1996 | 12 | 7 | 19 |
| 1997 | 12 | 9 | 21 |
| 1998 | 21 | 4 | 25 |
| 1999 | 14 | 6 | 20 |
| 2000 | 8 | 3 | 11 |
| 2001 | 11 | 6 | 17 |
| 2002 | 5 | 1 | 6 |
| 2003 | 10 | 3 | 13 |
| 2004 | 5 | 5 | 10 |
| 2005 | 5 | 8 | 13 |
| 2006 | 3 | 3 | 6 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 2 | 4 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 5 | 0 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tacrolimus" by people in Profiles.
-
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024 08 27; 8(16):4294-4310.
-
Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation. 2024 08 01; 108(8):1782-1792.
-
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Ann Transplant. 2024 Mar 12; 29:e943498.
-
Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay? Am J Clin Pathol. 2024 Jan 04; 161(1):97-106.
-
Impact of Renal Replacement Therapy on Rejection among Liver Transplant Recipients. Prog Transplant. 2023 12; 33(4):348-355.
-
Elevated tacrolimus levels among COVID-19 kidney transplant recipients are associated with worse disease severity and clinical outcomes. Clin Nephrol. 2023 Nov; 100(5):216-223.
-
Immunosuppression in Uterus Transplantation: Experience From the Dallas Uterus Transplant Study. Transplantation. 2023 03 01; 107(3):729-736.
-
Nanofiber-coated, tacrolimus-eluting sutures inhibit post-operative neointimal hyperplasia in rats. J Control Release. 2023 01; 353:96-104.
-
Impact of Steroid Only Induction on Rejection in Simultaneous Liver-Kidney Transplantation. Prog Transplant. 2022 12; 32(4):363-369.
-
Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 05 01; 106(5):997-1003.